Natixis Advisors LLC Purchases 1,593 Shares of Penumbra, Inc. $PEN

Natixis Advisors LLC increased its position in shares of Penumbra, Inc. (NYSE:PEN) by 4.1% during the 4th quarter, Holdings Channel reports. The fund owned 40,772 shares of the company’s stock after buying an additional 1,593 shares during the quarter. Natixis Advisors LLC’s holdings in Penumbra were worth $12,676,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of PEN. William Blair Investment Management LLC bought a new position in Penumbra during the 4th quarter worth approximately $107,567,000. Holocene Advisors LP bought a new position in Penumbra during the 3rd quarter worth approximately $78,585,000. Man Group plc boosted its stake in Penumbra by 1,862.2% during the 2nd quarter. Man Group plc now owns 206,461 shares of the company’s stock worth $52,984,000 after acquiring an additional 195,939 shares during the last quarter. AQR Capital Management LLC boosted its stake in Penumbra by 139.4% during the 2nd quarter. AQR Capital Management LLC now owns 330,990 shares of the company’s stock worth $84,939,000 after acquiring an additional 192,734 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Penumbra during the 3rd quarter worth approximately $43,476,000. Institutional investors own 88.88% of the company’s stock.

Penumbra Stock Performance

Shares of PEN opened at $320.51 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.95 and a current ratio of 6.02. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41. The firm’s 50 day moving average price is $326.86 and its two-hundred day moving average price is $326.01. The firm has a market cap of $12.61 billion, a P/E ratio of 73.85, a PEG ratio of 1.96 and a beta of 0.71.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The business had revenue of $374.76 million during the quarter, compared to the consensus estimate of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.83 EPS. On average, analysts forecast that Penumbra, Inc. will post 5.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Evercore reissued an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research note on Thursday, May 7th. UBS Group reissued a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, February 26th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research note on Saturday, May 9th. Finally, Citigroup cut their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $361.33.

Insider Activity at Penumbra

In other news, Director Harpreet Grewal sold 100 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total value of $32,822.00. Following the sale, the director owned 8,719 shares of the company’s stock, valued at $2,861,750.18. The trade was a 1.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.